Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial …

This work provides a systematic review of the literature from January 2003 to April 2014
pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of …

PURPOSE To provide guidance regarding best practices in the prevention and
management of medication-related osteonecrosis of the jaw (MRONJ) in patients with …

American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related
Osteonecrosis of the Jaws—2009 Update - Journal of Oral and Maxillofacial Surgery Skip to …

Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of
denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal …

The aim of this systematic review was to answer the question: What are the treatments
available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their …

PURPOSE: Osteonecrosis of the jaw (ONJ) is a serious complication associated with
bisphosphonate therapy, but its epidemiology in the setting of oral bisphosphonate therapy …

Purpose The reported incidence of osteonecrosis of the jaw (ONJ) ranges from 0.94% to
18.6%. This cohort study aimed to calculate the incidence of and identify the risk factors for …

Osteonecrosis of the jaw (ONJ) has been associated with antiresorptive therapy in both
oncology and osteoporosis patients. This debilitating condition is very rare and advances in …